Karin van der Tuin1, Arjen R Mensenkamp2, Carli M J Tops3, Eleonora P M Corssmit4, Winand N Dinjens5, Anouk N A van de Horst-Schrivers6, Jeroen C Jansen7, Mirjam M de Jong8, Henricus P M Kunst9, Benno Kusters10, Edward M Leter11, Hans Morreau12, Bernadette M P van Nesselrooij13, Rogier A Oldenburg14, Liesbeth Spruijt2, Frederik J Hes1, Henri J L M Timmers15. 1. Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands. 2. Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. 3. Department of Clinical Genetics, Laboratory for Diagnostic Genetic Analysis, Leiden University Medical Center, Leiden, the Netherlands. 4. Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands. 5. Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands. 6. Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 7. Department of Otorhinolaryngology, Leiden University Medical Center, Leiden, the Netherlands. 8. Department of Clinical Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 9. Department Otorhinolaryngology, Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands. 10. Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands. 11. Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands. 12. Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. 13. Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands. 14. Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands. 15. Department of Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands.
Abstract
Context: Paraganglioma (PGL) has the highest degree of heritability among human neoplasms. Current clinical understanding of germline SDHA mutation carriers is limited. Objective: To estimate the contribution of SDHA mutations in PGL and to assess clinical manifestations and age-related penetrance. Design: Nationwide retrospective cohort study. Setting: Tertiary referral centers in the Netherlands (multicenter). Patients: Germline SDHA analysis was performed in 393 patients with genetically unexplained PGL. Subsequently, 30 index SDHA mutation carriers and 56 nonindex carriers were studied. Main Outcome Measures: SDHA mutation detection yield, clinical manifestations, and SDHA-related disease penetrance. Results: Pathogenic germline SDHA variants were identified in 30 of the 393 referred patients with PGL (7.6%), who had head and neck PGL (21 of 174 [12%]), pheochromocytoma (4 of 191 [2%]), or sympathetic PGL (5 of 28 [18%]). The median age at diagnosis was 43 years (range, 17 to 81 years) in index SDHA mutation carriers compared with 52 years (range, 7 to 90 years) in nonmutation carriers (P = 0.002). The estimated penetrance of any SDHA-related manifestation was 10% at age 70 years (95% confidence interval, 0% to 21%) in nonindex mutation carriers. Conclusion: Germline SDHA mutations are relatively common (7.6%) in patients with genetically unexplained PGL. Most index patients presented with apparently sporadic PGL. In this SDHA series, the largest assembled so far, we found the lowest penetrance of all major PGL predisposition genes. This suggests that recommendations for genetic counseling of at-risk relatives and stringency of surveillance for SDHA mutation carriers might need to be reassessed.
Context:Paraganglioma (PGL) has the highest degree of heritability among humanneoplasms. Current clinical understanding of germline SDHA mutation carriers is limited. Objective: To estimate the contribution of SDHA mutations in PGL and to assess clinical manifestations and age-related penetrance. Design: Nationwide retrospective cohort study. Setting: Tertiary referral centers in the Netherlands (multicenter). Patients: Germline SDHA analysis was performed in 393 patients with genetically unexplained PGL. Subsequently, 30 index SDHA mutation carriers and 56 nonindex carriers were studied. Main Outcome Measures: SDHA mutation detection yield, clinical manifestations, and SDHA-related disease penetrance. Results: Pathogenic germline SDHA variants were identified in 30 of the 393 referred patients with PGL (7.6%), who had head and neck PGL (21 of 174 [12%]), pheochromocytoma (4 of 191 [2%]), or sympathetic PGL (5 of 28 [18%]). The median age at diagnosis was 43 years (range, 17 to 81 years) in index SDHA mutation carriers compared with 52 years (range, 7 to 90 years) in nonmutation carriers (P = 0.002). The estimated penetrance of any SDHA-related manifestation was 10% at age 70 years (95% confidence interval, 0% to 21%) in nonindex mutation carriers. Conclusion: Germline SDHA mutations are relatively common (7.6%) in patients with genetically unexplained PGL. Most index patients presented with apparently sporadic PGL. In this SDHA series, the largest assembled so far, we found the lowest penetrance of all major PGL predisposition genes. This suggests that recommendations for genetic counseling of at-risk relatives and stringency of surveillance for SDHA mutation carriers might need to be reassessed.
Authors: Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens Journal: Endocr Pathol Date: 2021-01-12 Impact factor: 3.943
Authors: Katerina Hadrava Vanova; Ying Pang; Linda Krobova; Michal Kraus; Zuzana Nahacka; Stepana Boukalova; Svetlana D Pack; Renata Zobalova; Jun Zhu; Thanh-Truc Huynh; Ivana Jochmanova; Ondrej Uher; Sona Hubackova; Sarka Dvorakova; Timothy J Garrett; Hans K Ghayee; Xiaolin Wu; Bjoern Schuster; Philip E Knapp; Zdenek Frysak; Igor Hartmann; Naris Nilubol; Jiri Cerny; David Taieb; Jakub Rohlena; Jiri Neuzil; Chunzhang Yang; Karel Pacak Journal: J Natl Cancer Inst Date: 2022-01-11 Impact factor: 13.506
Authors: Laurence Amar; Karel Pacak; Olivier Steichen; Scott A Akker; Simon J B Aylwin; Eric Baudin; Alexandre Buffet; Nelly Burnichon; Roderick J Clifton-Bligh; Patricia L M Dahia; Martin Fassnacht; Ashley B Grossman; Philippe Herman; Rodney J Hicks; Andrzej Januszewicz; Camilo Jimenez; Henricus P M Kunst; Dylan Lewis; Massimo Mannelli; Mitsuhide Naruse; Mercedes Robledo; David Taïeb; David R Taylor; Henri J L M Timmers; Giorgio Treglia; Nicola Tufton; William F Young; Jacques W M Lenders; Anne-Paule Gimenez-Roqueplo; Charlotte Lussey-Lepoutre Journal: Nat Rev Endocrinol Date: 2021-05-21 Impact factor: 43.330
Authors: Bruna Calsina; Shahida Flores; Sophie Giraud; Marion Lenglet; Alexandre Buffet; Pauline Romanet; Elisa Deflorenne; Javier Aller; Isabelle Bourdeau; Brigitte Bressac-de Paillerets; María Calatayud; Caroline Dehais; Erwan De Mones Del Pujol; Atanaska Elenkova; Philippe Herman; Peter Kamenický; Sophie Lejeune; Jean Louis Sadoul; Anne Barlier; Stephane Richard; Judith Favier; Nelly Burnichon; Betty Gardie; Patricia L Dahia; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo Journal: J Med Genet Date: 2020-01-29 Impact factor: 6.318